Original language | English (US) |
---|---|
Pages (from-to) | 873-874 |
Number of pages | 2 |
Journal | Journal of Allergy and Clinical Immunology |
Volume | 144 |
Issue number | 3 |
DOIs | |
State | Published - Sep 2019 |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Allergy and Clinical Immunology, Vol. 144, No. 3, 09.2019, p. 873-874.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Reply
AU - AsthmaNet Investigators
AU - Cardet, Juan Carlos
AU - Jiang, Xiaofeng
AU - Lu, Quan
AU - Gerard, Norma
AU - McIntire, Kristen
AU - Boushey, Homer A.
AU - Castro, Mario
AU - Chinchilli, Vernon M.
AU - Codispoti, Christopher D.
AU - Dyer, Anne Marie
AU - Holguin, Fernando
AU - Kraft, Monica
AU - Lazarus, Stephen
AU - Lemanske, Robert F.
AU - Lugogo, Njira
AU - Mauger, Dave
AU - Moore, Wendy C.
AU - Moy, James
AU - Ortega, Victor E.
AU - Peters, Stephen P.
AU - Smith, Lewis J.
AU - Solway, Julian
AU - Sorkness, Christine A.
AU - Sumino, Kaharu
AU - Wechsler, Michael E.
AU - Wenzel, Sally
AU - Israel, Elliot
N1 - Funding Information: Supported by grants HL098102, U10HL098096, UL1TR000150, UL1TR000430, UL1TR000050, HL098075, UL1TR001082, HL098090, HL098177, UL1TR000439, HL098098, UL1TR000448, HL098107, HL098112, HL098103, UL1TR000454, and HL098115 awarded by the National Heart, Lung, and Blood Institute.Disclosure of potential conflict of interest: J. C. Cardet reports grants from the National Institute of Allergy and Infectious Diseases (NIAID) during the conduct of the study. M. Castro reports grants from the National Institutes of Health (NIH) and American Lung Association during the conduct of the study and personal fees from Aviragen, Boehringer Ingelheim, Boston Scientific, Elsevier, Genentech, GlaxoSmithKline, Holaira, and Teva; grants from Amgen, Boehringer Ingelheim, Genentech, Gilead, GlaxoSmithKline, Invion, MedImmune, sanofi-aventis, and Vectura all outside the submitted work. V. M. Chinchilli, S. P. Peters, and S. Lazarus report grants from the NIH/National Heart, Lung, and Blood Institute (NHLBI) during the conduct of the study. A.-M. Dyer reports grants from the NHLBI during the conduct of the study. M. Kraft reports grants from the NIH, Roche, Sanofi, and Chiesi and other support from TEVA, AstraZeneca, and Elsevier outside the submitted work. R. F. Lemanske reports grants from the NHLBI during the conduct of the study; nonfinancial support from the American Academy of Allergy, Asthma & Immunology (AAAAI); grants from the Clinical and Translational Science Award from the NIH; personal fees from LSU, Elsevier, and UpToDate; and grants from Childhood Origins of Asthma (COAST) and AsthmaNet outside the submitted work. N. Lugogo reports personal fees from AstraZeneca and consulting fees from TEVA, outside the submitted work. D. Mauger reports grants from the NIH during the conduct of the study and nonfinancial support from GlaxoSmithKline, Merck, and TEVA outside the submitted work. W. C. Moore reports grants from the NIH/NHLBI during the conduct of the study, grants and personal fees from AstraZeneca and Sanofi Regeneron, and grants from Boehringer Ingelheim, GlaxoSmithKline, Pearl Therapeutics, and Novartis outside the submitted work. J. Solway reports consulting fees from Sanofi, Genzyme, and Regeneron and gifts from the Rafael Rivera III Memorial Foundation for Asthma Research to the University of Chicago that were designated for asthma research in his laboratory. M. E. Wechsler reports personal fees from AstraZeneca, BSCI, Novartis, Vectura, Regeneron, Genentech, Sentien, and Boehringer Ingelheim and grants and personal fees from Teva, GlaxoSmithKline, and Sanofi, all outside the submitted work. S. Wenzel reports grants and personal fees from AstraZeneca and Sanofi; grants from Boehringer Ingelheim, GlaxoSmithKline, and Novartis; and personal fees from Pieris and UpToDate outside the submitted work. E. Israel reports personal fees from AstraZeneca, Novartis, Philips Respironics, Regeneron Pharmaceuticals, TEVA Specialty Pharmaceuticals, Bird Rock Bio, Nuvelution Pharmaceuticals, Vitaeris, Sanofi, Merck, Entrinsic Health Solutions, and GlaxoSmithKline; other support from Vorso, Pneuma Respiratory, and 4D Pharma; grants from Genentech, Sanofi, and Boehringer Ingelheim; and nonfinancial support from Boehringer Ingelheim, GlaxoSmithKline, Merck, Sunovion, TEVA, and TEVA Specialty Pharmaceuticals outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: Supported by grants HL098102 , U10HL098096 , UL1TR000150 , UL1TR000430 , UL1TR000050 , HL098075 , UL1TR001082 , HL098090 , HL098177 , UL1TR000439 , HL098098 , UL1TR000448 , HL098107 , HL098112 , HL098103 , UL1TR000454 , and HL098115 awarded by the National Heart, Lung, and Blood Institute .
PY - 2019/9
Y1 - 2019/9
UR - http://www.scopus.com/inward/record.url?scp=85071232529&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071232529&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2019.05.029
DO - 10.1016/j.jaci.2019.05.029
M3 - Letter
C2 - 31300279
AN - SCOPUS:85071232529
SN - 0091-6749
VL - 144
SP - 873
EP - 874
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 3
ER -